TY  - JOUR
AU  - Balar, Arjun V
AU  - Galsky, Matthew D
AU  - Rosenberg, Jonathan E
AU  - Powles, Thomas
AU  - Petrylak, Daniel P
AU  - Bellmunt, Joaquim
AU  - Loriot, Yohann
AU  - Necchi, Andrea
AU  - Hoffman-Censits, Jean
AU  - Perez-Gracia, Jose Luis
AU  - Dawson, Nancy A
AU  - van-der-Heijden, Michiel S
AU  - Dreicer, Robert
AU  - Srinivas, Sandy
AU  - Retz, Margitta M
AU  - Joseph, Richard W
AU  - Drakaki, Alexandra
AU  - Vaishampayan, Ulka N
AU  - Sridhar, Srikala S
AU  - Quinn, David I
AU  - Duran, Ignacio
AU  - Shaffer, David R
AU  - Eigl, Bernhard J
AU  - Grivas, Petros D
AU  - Yu, Evan Y
AU  - Li, Shi
AU  - Kadel, Edward E
AU  - Boyd, Zachary
AU  - Bourgon, Richard
AU  - Hegde, Priti S
AU  - Mariathasan, Sanjeev
AU  - Thåström, AnnChristine
AU  - Abidoye, Oyewale O
AU  - Fine, Gregg D
AU  - Bajorin, Dean F
AU  - IMvigor210 Study Group
PY  - 2016
DO  - 10.1016/S0140-6736(16)32455-2
UR  - http://hdl.handle.net/10668/10669
T2  - Lancet (London, England)
AB  - First-line chemotherapy for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma is associated with short response duration, poor survival, and high toxicity. This study assessed atezolizumab (anti-programmed...
LA  - en
PB  - The Lancet Publishing Group
KW  - Antibodies, Monoclonal
KW  - B7-H1 Antigen
KW  - Cisplatin
KW  - Humans
KW  - Lymphatic Metastasis
KW  - Response Evaluation Criteria in Solid Tumors
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Agents
KW  - Biomarkers, Tumor
KW  - Carcinoma, Transitional Cell
KW  - Contraindications
KW  - Female
KW  - Infusions, Intravenous
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Middle Aged
KW  - Urologic Neoplasms
TI  - Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
TY  - research article
VL  - 389
ER  -